Table 1. Patient characteristics.
| Variables | Development cohort (n=297) | Evaluation cohort (n=99) |
|---|---|---|
| Median age [IQR] (years) | 62 [55–72] | 61 [51–71] |
| Median PSA [IQR] (ng/mL) | 6.7 [4.6–10.1] | 6.9 [5.1–12.1] |
| Scanner | ||
| Verio | 77 | 27 |
| Skyra | 175 | 58 |
| Prisma | 45 | 14 |
| Number of patients with MRI-detected lesions | ||
| 1 lesion | 212 | 70 |
| 2 lesions | 45 | 18 |
| 3 lesions | 33 | 8 |
| 4 lesions | 7 | 3 |
| Number of MRI-detected lesions | ||
| Total | 429 | 142 |
| Peripheral zone | 300 | 102 |
| Transition zone | 129 | 40 |
| Gleason grade group (Gleason score) | ||
| Gleason grade group 1 (GS 3 + 3) | 99 | 69 |
| Gleason grade group 2 (GS 3 + 4) | 76 | 20 |
| Gleason grade group 3 (GS 4 + 3) | 95 | 22 |
| Gleason grade group 4 (GS =8) | 47 | 21 |
| Gleason grade group 5 (GS >8) | 112 | 10 |
PSA, prostate-specific antigen; IQR, interquartile range; MRI, magnetic resonance imaging; GS, Gleason score.